TC Home

The only technical publication dedicated to readers who formulate, manufacture, or package solid dosage forms.

Slide background
Slide background
  • April 14, 2020

NEW HAVEN, CT—The FDA approved Nurtec (rimegepant) orally dissolving tablet (ODT) as an acute treatment for adults suffering from migraines. The product is owned by Biohaven Pharmaceuticals, which partnered with Catalent to create the migraine treatment. Using Catalent’s Zydis ODT platform, the companies created a freeze-dried tablet that disperses almost instantly in the mouth without water, allowing patients to treat their migraines in a convenient and discreet manner. The ODT is Biohaven’s first FDA-approved product and is currently the first and only calcitonin gene-related peptide receptor antagonist available in a fast-acting ODT.